Fox Run Management’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $298K | Buy |
31,792
+13,289
| +72% | +$125K | 0.05% | 639 |
|
|
2025
Q1 | $132K | Buy |
+18,503
| New | +$132K | 0.02% | 847 |
|
|
2024
Q1 | – | Sell |
-19,038
| Closed | -$580K | – | 980 |
|
|
2023
Q4 | $580K | Buy |
19,038
+8,282
| +77% | +$253K | 0.15% | 244 |
|
|
2023
Q3 | $340K | Buy |
+10,756
| New | +$340K | 0.1% | 394 |
|
|
2023
Q2 | – | Sell |
-11,119
| Closed | -$414K | – | 875 |
|
|
2023
Q1 | $414K | Buy |
+11,119
| New | +$414K | 0.14% | 283 |
|
|
2022
Q2 | – | Sell |
-4,578
| Closed | -$333K | – | 679 |
|
|
2022
Q1 | $333K | Buy |
+4,578
| New | +$333K | 0.19% | 236 |
|
|
2018
Q1 | – | Sell |
-11,970
| Closed | -$230K | – | 861 |
|
|
2017
Q4 | $230K | Buy |
+11,970
| New | +$230K | 0.07% | 537 |
|